Q00987 (MDM2_HUMAN) Homo sapiens (Human)

E3 ubiquitin-protein ligase Mdm2 UniProtKBInterProSTRINGInteractive Modelling

491 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5; Isoform 6; Isoform 7; Isoform 8; Isoform 9; Isoform 10; Isoform 11)

Available Structures

126 Experimental Structures

DescriptionOligo-stateLigandsStructureRange
Structure of complex of MDM2(3-109) and P73 TAD(10-25) Heteromer
O15350;
3-109
Assess
Green fluorescent protein linked MTide-02 inhibitor in complex with mdm2 Heteromer
GOL;PO4;PG4;15-110
Assess
MDM2 bound CueO-PM2 sensor Heteromer
P36649;
25-111
Assess
Crystal structure of the computationally designed chemically disruptable heterodimer LD6-MDM2 Heteromer
Q328D2;
25-110
Assess
Crystal structure of p53 epitope-scaffold based on a inhibitor of cysteine proteases in complex wit… Heteromer
CL;SO4;GOL;26-110
Assess
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 Heteromer
P04637;
25-109
Assess
Crystal structure of human MDM2 in complex with a potent miniature protein inhibitor (18-residues) Heteromer
ACT;CL;27-109
Assess
Crystal Structure of an MDM2/P53 Peptide Complex Heteromer
P04637;
SO4;26-108
Assess
Solution structure of Hdm2 with engineered cyclotide Heteromer
27-109
Assess
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Heteromer
O15151;
ZN;428-491
Assess
Structure of MDM2-MDMX-UbcH5B-ubiquitin complex Heteromer
O15151; P0CG47; P62837;
ZN;SO4;429-491
Assess
Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B-Ub Heteromer
P62837; P62979;
ZN;CL;NO3;430-491
Assess
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 1) Heteromer
P0CG47; P62837;
CL;ZN;EDO;430-491
Assess
Crystal structure of human MDM2-G443T RING domain homodimer bound to UbcH5B-Ub (Crystal form 2) Heteromer
P0CG47; P62837;
CL;ZN;EDO;430-491
Assess
Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Heteromer
O15151;
ZN;432-491
Assess
Crystal structure of human MDM2-RPL11 Heteromer
P62913;
IMD;BME;ZN;293-334
Assess
Crystal Structure of the USP7:Hdm2(PSTS) complex Heteromer
Q93009;
395-401
Assess
The Crystal Structure of the N-terminal domain of HAUSP/USP7 complexed with mdm2 peptide 147-150 Heteromer
Q93009;
145-150
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITORhomo-3-merIMZ;25-109
Assess
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.homo-2-mer6GG;11-111
Assess
Structure of Human MDM2 in complex with a Benzodiazepine Inhibitorhomo-2-merDIZ;16-111
Assess
Structure of a stapled peptide antagonist bound to Nutlin-resistant Mdm2.homo-2-mer18-112
Assess
Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.homo-2-mer6GG;18-111
Assess
Inhibitor of MDM2-p53 Interactionhomo-2-merTVH;17-110
Assess
X-ray structure of the p53-MDM2 inhibitor NMI801 bound to HDM2 at 2.1A resolutionhomo-2-merH0W;19-111
Assess
Crystal structure of human MDM2 with a 12-mer peptide inhibitor PMI (N8A mutant)homo-2-merCL;25-109
Assess
Structure of hDM2 with Dimer Inducing Indolyl Hydantoin RO-2443homo-2-mer03M;25-109
Assess
Crystal structure of human MDM2 in complex with a 12-mer peptide inhibitorhomo-2-merGAI;26-109
Assess
Crystal structure of human MDM2 in complex with D-peptide inhibitor (DPMI-alpha)homo-2-merSO4;CL;26-108
Assess
Solution Structure of Hdm2 RING Finger Domainhomo-2-merZN;429-491
Assess
NMR Structure of Mdm2 (6-125) with Pip-1monomer13Q;1-125
Assess
NMR structure of unliganded MDM2monomer1-118
Assess
Ordering of the N Terminus of Human MDM2 by Small Molecule Inhibitorsmonomer0Y7;6-111
Assess
Co-crystal Structure of MDM2 in Complex with AM-7209monomer3UD;SO4;6-110
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 4monomer2U0;SO4;6-110
Assess
MDM2 in complex with SAR405838monomer7HC;SO4;GOL;10-111
Assess
Co-Crystal Structure of MDM2 with Inhbitor Compound 3monomer2U5;SO4;11-110
Assess
Co-Crystal Structure of MDM2 with Inhbitor Compound 46monomer2U6;SO4;12-110
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 47monomer2U1;12-110
Assess
Chemical Shift Assignments for MIP and MDM2 in bound statemonomer6-102
Assess
Structure of the stapled peptide YS-01 bound to MDM2monomer17-112
Assess
Structure of the stapled peptide YS-02 bound to MDM2monomer17-112
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidinemonomer62T;SO4;18-113
Assess
Structure of MDM2 with low molecular weight inhibitormonomerB5K;18-113
Assess
Human MDM2 liganded with a 12mer peptide inhibitor (pDI6W)monomer17-112
Assess
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-bas…monomer6ZT;SO4;CL;17-111
Assess
Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acidsmonomer18-112
Assess
HDM2 in complex with compound 63monomer1I9;GOL;CL;17-111
Assess
HDM2 in complex with compound 56monomer1I0;17-111
Assess
Structure of Mdm2 with low molecular weight inhibitormonomer4NJ;18-112
Assess
HDM2 in complex with compound 62monomer1I3;SO4;17-111
Assess
Discovery of New Natural-product-inspired Spiro-oxindole Compounds as Orally Active Inhibitors of t…monomerGOL;SO4;6SS;17-111
Assess
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 9 AT 1.13A; Structural states of Hdm2 and HdmX: X-r…monomerHTZ;CL;18-111
Assess
HDM2 (17-111, WILDTYPE) COMPLEXED WITH COMPOUND 10 AT 1.21A; Structural states of Hdm2 and HdmX: X-…monomerHU8;17-110
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer6SJ;SO4;18-111
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer6ST;ZN;SO4;18-111
Assess
Crystal structure of MDM2 in complex with compound 13.monomerH28;GOL;SO4;18-111
Assess
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitormonomerEYH;CL;18-111
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH NVP-HDM201 AT 1.56Amonomer9QW;CL;19-111
Assess
Structure of human MDM2 protein in complex with Mi-63-analogmonomerMI6;18-110
Assess
Exhaustive Fluorine Scanning towards Potent p53-MDM2 Antagonistmonomer07G;18-110
Assess
Co-crystal structure of MDM2 with inhibitor (2'S,3R,4'S,5'R)-N-(2-aminoethyl)-6-chloro-4'-(3-chloro…monomer1MT;18-110
Assess
co-crystal structure of MDM2 (17-111) with compound 16, {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…monomer35S;18-110
Assess
co-crystal structure of MDM2 (17-111) in complex with compound 25monomer2SW;18-110
Assess
Novel Spiro[3H-indole-3,2 -pyrrolidin]-2(1H)-one Inhibitors of the MDM2-p53 Interaction: HDM2 (MDM2…monomer6SK;SO4;19-111
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidinemonomer62R;SO4;21-113
Assess
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …monomer4T4;CL;18-110
Assess
co-crystal structure of MDM2(17-111) in complex with compound 48monomer2TZ;18-110
Assess
The Central Valine Concept Provides an Entry in a New Class of Non Peptide Inhibitors of the P53-MD…monomerBLF;18-110
Assess
Structure of a novel submicromolar MDM2 inhibitormonomerY30;SO4;18-110
Assess
Structure of Mdm2 with low molecular weight inhibitor.monomer4NX;18-110
Assess
crystal structure of MDM2 with chromenotriazolopyrimidine 1monomerYIN;18-110
Assess
Co-Crystal Structure of MDM2 with Inhibitor Compound 49monomer2U7;18-110
Assess
Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interactionmonomer2V8;18-110
Assess
Co-crystal structure of MDM2 with inhibitor (2R,3E)-2-[(2S,3R,6S)-2,3-bis(4-chlorophenyl)-6-(4-fluo…monomer1MQ;18-110
Assess
Crystal Structure of HDM2 in complex with Nutlin-3amonomerNUT;SO4;CL;IOD;20-111
Assess
HDM2 in complex with a beta-hairpinmonomerSO4;MPO;23-114
Assess
Inhibitor of MDM2-p53 InteractionmonomerDMS;EDO;SO4;TVK;17-108
Assess
Co-crystal structure of MDM2 with Inhibitor Compound 4monomer2TW;19-110
Assess
Structure of a stapled peptide bound to MDM2monomerO9E;17-108
Assess
Inhibitor of MDM2-p53 InteractionmonomerDMS;EDO;SO4;TUW;17-108
Assess
crystal structure of compound 16 bound to MDM2(17-111), {(3R,5R,6S)-5-(3-CHLOROPHENYL)-6-(4-CHLOROP…monomer35T;19-110
Assess
Inhibitor of MDM2-p53 InteractionmonomerEDO;U3Z;17-108
Assess
crystal structure of MDM2 (17-111) in complex with compound 29 (AM-8553)monomer0R3;19-110
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 11 AT 2.0A; Structural states of Hdm2 and HdmX: X-…monomerHRH;19-110
Assess
Inhibitor of MDM2-p53 InteractionmonomerSO4;TUZ;17-108
Assess
Inhibitor of MDM2-p53 InteractionmonomerSO4;TV5;17-108
Assess
Co-crystal structure of MDM2 with inhibitor {(2S,5R,6S)-6-(3-chlorophenyl)-5-(4-chlorophenyl)-4-[(2…monomer1MY;19-110
Assess
Crystal Structure of an MDM2/Nutlin-3a complexmonomerNUT;SO4;18-108
Assess
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical …monomer4TH;CL;20-110
Assess
Crystal structure of Mdm2 bound to a stapled peptidemonomerFL5;18-108
Assess
crystal structure of MDM2 (17-111) in complex with compound 23monomer0R2;SO4;22-111
Assess
X-ray structure of Mdm2 with modified p53 peptidemonomer24-113
Assess
Structure of a novel submicromolar MDM2 inhibitormonomerTJ2;K;21-110
Assess
HDM2 in complex with compound 2monomer1GI;SO4;CIT;24-112
Assess
Crystal structure of HIS6-tagged Mdm2 with nutlin-3amonomerNUT;24-111
Assess
MDM2 in complex with an 8-mer p53 peptide analoguemonomer25-112
Assess
Structure of human MDM2 in complex with an optimized p53 peptidemonomerSO4;23-110
Assess
The 1.25A Crystal structure of His6-tagged Mdm2 in complex with nutlin-3amonomerNUT;24-110
Assess
Crystal structure of hDM2 in complex with a C-terminal triurea capped peptide chimera foldamer.monomerUCV;25-111
Assess
Structure of human MDM2 in complex with high affinity peptidemonomer25-111
Assess
HDM2 (17-111, WILD TYPE) COMPLEXED WITH COMPOUND 12 AT 1.8A; Structural states of Hdm2 and HdmX: X-…monomerHRE;SO4;25-111
Assess
Structure of the Stapled p53 Peptide Bound to Mdm2monomerCL;24-110
Assess
X-RAY STRUCTURE OF HDM2/CMR19 AT 1.45A: Discovery, X-ray structure and CPP-conjugation enabled upta…monomerSO4;26-111
Assess
Mdm2 in complex with a D amino Acid Containing Stapled Peptidemonomer26-111
Assess
Structure of a novel submicromolar MDM2 inhibitormonomer28W;25-110
Assess
HDM2 in complex with a 3,3-Disubstituted Piperidinemonomer62Q;26-111
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA)monomerPEG;IPA;CL;25-109
Assess
Macrocyclization of an all-D linear peptide improves target affinity and imparts cellular activity:…monomer25-109
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomerEPE;DMS;M9E;25-109
Assess
Crystal structure of human MDM2 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate…monomer25-109
Assess
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitormonomerLTZ;SO4;25-109
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomerM9H;25-109
Assess
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-bromophenyl)-4-methylmorp…monomer1MN;SO4;26-110
Assess
Structure of human MDM2 protein in complex with a small molecule inhibitormonomerK23;SO4;26-110
Assess
Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Pro…monomer25-109
Assess
Co-crystal structure of MDM2 with inhibitor (2S,5R,6S)-2-benzyl-5,6-bis(4-chlorophenyl)-4-methylmor…monomer1MO;SO4;26-110
Assess
Crystal structure of human mdm2 with a dihydroimidazothiazole inhibitormonomerVZV;25-109
Assess
Crystal structure of human MDM2 in complex with a trifluoromethylated D-peptide inhibitormonomerSO4;26-109
Assess
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with…monomer4SS;25-108
Assess
Human MDM2 liganded with a 12mer peptide inhibitor (pDIQ)monomerEDO;26-108
Assess
Structure of the Stapled Peptide Bound to Mdm2monomerP07;26-108
Assess
CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3monomer27-108
Assess
Crystal structure of human MDM2 complexed with D-peptide (12 residues)monomer26-107
Assess
Solution structure of the C4 zinc-finger domain of HDM2monomerZN;290-335
Assess
Solution structure of the C4 zinc-finger domain of HDM2monomerZN;290-335
Assess

2 Homology models

Oligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
homo-2-mer6GG;0.825j7f.1.A11-111
100.00
Assess
homo-2-merZN;0.757ahz.1.A436-490
85.29
Assess

19 Homology models built on isoform sequence

IsoformOligo-stateLigandsQMEANDisCoTemplateRangeSeq id (%)
Isoform 2monomerZN;0.686sqp.1.B229-296
91.18
Assess
Isoform 3monomerZN;0.706sqp.1.B203-270
91.18
Assess
Isoform 3monomerZN;0.534xxb.1.B77-113
97.78
Assess
Isoform 4homo-2-merZN;0.757ahy.1.A161-217
85.29
Assess
Isoform 4monomerZN;0.524xxb.1.B22-61
96.38
Assess
Isoform 5monomerZN;0.666sqp.1.B254-321
91.18
Assess
Isoform 5monomer0.532lzg.1.A1-58
91.38
Assess
Isoform 5monomer0.531z1m.1.A1-58
91.38
Assess
Isoform 6monomerZN;0.675mnj.1.C70-132
100.00
Assess
Isoform 7monomer0.735j7f.1.B12-93
84.95
Assess
Isoform 8homo-2-merZN;0.757ahz.1.A375-429
85.29
Assess
Isoform 8monomer0.662axi.1.A1-53
100.00
Assess
Isoform 9monomerZN;0.757ahz.1.A391-445
85.29
Assess
Isoform 9monomer0.584hbm.1.A6-66
100.00
Assess
Isoform 10homo-2-mer6GG;0.815j7f.1.A11-111
100.00
Assess
Isoform 10homo-2-merZN;0.767ahz.1.A381-435
85.29
Assess
Isoform 11homo-2-mer6GG;0.825j7f.1.A17-117
100.00
Assess
Isoform 11homo-2-merZN;0.757ahz.1.A442-496
85.29
Assess
Isoform 11monomerZN;0.564xxb.1.B299-340
100.00
Assess

Alignments